DEVELOPING CLINICALLY RELEVANT MODELS OF MUCINOUS OVARIAN CARCINOMA FOR TESTING THERAPIES.

Grant number: W81XWH-18-1-0226 | Funding period: 2018 - 2022

Completed

Abstract

PUBLIC ABSTRACT Mucinous ovarian cancer (MOC) is a rare type of ovarian cancer that is quite different to the other subtypes. Most women who get this disease at an advanced stage will die within 2 years because the standard ovarian drugs do not work, and doctors don’t have good evidence to help them choose other therapies. One of the ways we could help is to study tumors removed from women during their surgery, by growing them in the laboratory and then testing various drugs on them to see which ones will work. This strategy is one that has been successful for other tumor types. The problem with MOC is that when we try to grow the tumor in the laboratory, or put small pieces of tumor into mi..

View full description

Related publications (2)

Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

Nicola S Meagher, Kylie L Gorringe, Matthew Wakefield, Adelyn Bolithon, Chi Nam Ignatius Pang, Derek S Chiu, Michael S Anglesio, Kylie-Ann Mallitt, Jennifer A Doherty, Holly R Harris, Joellen M Schildkraut, Andrew Berchuck, Kara L Cushing-Haugen, Ksenia Chezar, Angela Chou, Adeline Tan, Jennifer Alsop, Ellen Barlow, Matthias W Beckmann, Jessica Boros

2022-12-15

PURPOSE: Advanced-stage mucinous ovarian carcinoma (MOC) has poor chemotherapy response and prognosis and lacks biomarkers to aid ..

Options for the Treatment of Mucinous Ovarian Carcinoma

Olivia Craig, Carolina Salazar, Kylie L Gorringe

2021-12-01

Complete surgical resection is the gold-standard treatment for all mucinous ovarian carcinoma (MOC) cases. Advanced-stage disease ..

University of Melbourne Researchers

Kylie Gorringe The Sir Peter Maccallum Department of Oncology